Pfeiffer, who was one of the initial investigators of Mauve, treated more than one thousand high-Mauve patients with vitamin B6 and zinc with very positive results. Symptom improvement with these supplements can be experienced in patients in as little as two days and Mauve levels have been observed to decrease by as much as 50% after one month of treatment. However, discontinuation of the supplement regime may result in deterioration of the patient in as little as 48 hours. Correlation studies have provided evidence of zinc and functional vitamin B6 deficiencies in high-Mauve patients, supporting the use of these nutrients in the treatment of Mauve. Many of the symptoms observed in high-Mauve patients can be attributed to zinc, vitamin B6 and biotin deficiencies. Furthermore, many neurotransmitters such as serotonin, dopamine and GABA require vitamin B6 and/or zinc for their production.
Multiple compounding factors have fuelled the opposition to the relevance of the Mauve Factor to mental health disorders. One area is the incorrect chemical identification of the Mauve Factor and the subsequent erroneous naming (kryptopyrrole) of this neurotoxic compound. Kryptopyrrole is the term that the Pfeiffer Centre has used in the past for the Mauve Factor and this term has been in use for more than 20 years. However, it has recently come to the attention of those involved in this area of research that the term ‘kryptopyrrole’ is scientifically inaccurate, and the Mauve Factor has been identified as hydroxyhemopyrrolin-2-one (HPL).
- Abdominal pain
- Impotence in males
- Irregular periods
- Anxiety Morning nausea
- Attention Deficit/Hyperactivity
NOTICE TO PATIENTS
WellLab practices in the usual practitioner-referral system for pathology laboratories. Patients are highly recommended to seek the supervision and guidance of a qualified healthcare practitioner for the interpretation of any lab results and associated information. WellLab can offer assistance in locating a suitable practitioner.